Le Lézard
Classified in: Health
Subjects: NPT, PSF

National Advertising Division Recommends Certain Modifications to Comparative Advertising for Jetty Insurance Agency's "Admitted" Surety Bond Product


NEW YORK, April 6, 2021 /PRNewswire/ -- The National Advertising Division (NAD) of BBB National Programs recommended that Jetty Insurance Agency, LLC modify its comparative advertising claims to clearly disclose the distinctions between its "admitted" surety bond product and LeaseLock, Inc.'s surplus-line lease insurance product. NAD further recommended that Jetty modify its advertising to avoid conveying unsupported messages regarding the damage coverage limits of the parties' respective products.

The claims at issue, which appeared in digital materials, email, sales presentations, sales sheets, and other advertising for the Jetty Security Deposit Alternative Plan were challenged by LeaseLock, Inc.

Both the advertiser and challenger offer security deposit alternatives to landlords and property managers, which reduce the up-front security deposit costs for renters. Security deposit alternatives are insurance programs that typically fall into one of two categories: surety bonds and lease insurance.

Jetty offers an "admitted" surety bond product. Being "admitted" means the provider offering the product has been licensed by the Department of Insurance (DOI) in the state (or states) where it is sold. As part of mandatory adherence to state regulations, the provider cannot modify the product's rates or coverage without regulatory approval. With "admitted" surety bonds, renters pay the advertiser either a one-time, nonrefundable fee that is significantly less than the traditional cash security deposit, or a low monthly fee. In exchange, Jetty covers the cost to the landlord of property damage or missed rent, and then seeks reimbursement from the renter through a collections process if the renter fails to settle their account at move out.

LeaseLock, in contrast, offers a lease insurance product. Lease insurance is regulated under surplus-line insurance regulations. LeaseLock pays a "surplus lines" tax to provide lease insurance and in return has the flexibility to modify product rates and coverage. LeaseLock, which is also licensed in every state it does business, insures the property management company, which chooses a coverage plan for the units managed. Renters pay a monthly fee in addition to their rent, and the property owner then pays LeaseLock in order to have the rental unit covered under this insurance.

At issue before NAD was whether Jetty's comparative marketing campaign overstates the benefits of its "admitted" status and its surety bond product and makes misleading comparisons with respect to the parties' damage coverage plans. NAD noted that Jetty's advertising seeks to compare two security deposit alternative products that operate under materially different regulatory schemes and structural parameters. While advertisers are free to make "apples-to-oranges" comparisons in order to highlight features or attributes of their products, advertisers must disclose the material differences between the products being compared.

NAD determined that a reasonable consumer takeaway from the challenged advertising is that Jetty's "admitted" product is superior to LeaseLock's surplus-line lease insurance product because it is more regulated and offers better or additional protections to policyholders. Because the evidence in the record was insufficient to support such a broad message, NAD recommended that Jetty modify its advertising to clearly disclose the material distinctions between the products, and to also avoid conveying the unsupported message that its "admitted" product is superior to the challenger's product because it is more regulated and offers better or additional protections to policyholders.

Regarding the challenged damage coverage claims, Jetty provides a coverage plan that allows damage claims up to the full policy limit without apportionment between rent and property damage, whereas LeaseLock's "standard" plan mandates such apportionment. While noting that this distinction is an important one, NAD determined that Jetty's unqualified damage cap claims (e.g., "Others cap damage protection at $500, which misses common claims . . .") communicate the unsupported message that LeaseLock's damage coverage is, without exception, limited to $500 in property damage. Further, NAD determined that Jetty's unqualified "No Damage Cap" and "zero caps on claims categories" convey the unsupported message that the advertiser's product offers unlimited, uncapped damage coverage that is not restricted by, or can exceed, the total policy limits. Therefore, NAD recommended that Jetty modify its advertising to avoid conveying such messages.

Finally, during the proceeding, Jetty agreed to discontinue numerous challenged claims, including, for example:

Therefore, NAD did not review these claims on the merits.

In its advertiser statement, Jetty stated that it agrees to comply with NAD's decision. The advertiser further stated that while it "respectfully disagrees with certain of NAD's conclusions . . . it intends to comply with NAD's recommendations to highlight in its advertising the 'material distinctions' between Jetty's 'admitted' surety bonds and LeaseLock's surplus line insurance.

All BBB National Programs case decisions can be found in the?case decision library.? 

About BBB National Programs: BBB National Programs is where businesses turn to enhance consumer trust and consumers are heard. The non-profit organization creates a fairer playing field for businesses and a better experience for consumers through the development and delivery of effective third-party accountability and dispute resolution programs. Embracing its role as an independent organization since the restructuring of the Council of Better Business Bureaus in June 2019, BBB National Programs today oversees more than a dozen leading national industry self-regulation programs, and continues to evolve its work and grow its impact by providing business guidance and fostering best practices in arenas such as advertising, child-directed marketing, and privacy.?To learn more, visit bbbprograms.org.

About the National Advertising Division: The?National Advertising Division (NAD) of BBB National Programs?provides?independent self-regulation?and dispute resolution services,?guiding?the truthfulness of advertising across the U.S. NAD?reviews national advertising in all media and its decisions set consistent standards for?advertising?truth and accuracy, delivering meaningful protection to?consumers?and leveling the playing field for business.??

SOURCE BBB National Programs


These press releases may also interest you

at 00:05
ImmunityBio, Inc. , an immunotherapy company, today announced positive overall survival results in the QUILT 3.055 study of 2nd- and 3rd-line NSCLC patients who progressed after checkpoint inhibitor therapy (pembrolizumab, nivolumab, or atezolizumab)...

at 00:05
The Insurance Institute for Highway Safety is updating its vehicle-to-vehicle front crash prevention test to address crashes that occur at higher speeds and those in which the struck vehicle is a motorcycle or large truck. Only one of the first 10...

at 00:00
Nutriessential.com recently announced its expansion into Oceania, Asia, and the Gulf. The company has been providing science-backed GMP-certified supplements in the US, Europe and Canada since 2005 and decided to expand owing to rising global demands...

24 avr 2024
Summit Clinical Research LLC ("Summit") is deeply saddened by the death of Co-Founder and Chairman Dr. Stephen Harrison. Summit mourns Dr. Harrison and extends its heartfelt condolences to his family and loved ones.   During an illustrious 30-year...

24 avr 2024
Shanghai Junshi Biosciences Co., Ltd ("Junshi Biosciences," HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, announced that the Drug...

24 avr 2024
Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune, ophthalmology...



News published on and distributed by: